These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32062041)

  • 41. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
    Koliani-Pace JL; Singh S; Luo M; Hirten R; Aniwan S; Kochhar G; Chang S; Lukin D; Gao Y; Bohm M; Swaminath A; Gupta N; Shmidt E; Meserve J; Winters A; Chablaney S; Faleck DM; Yang J; Huang Z; Boland BS; Shashi P; Weiss A; Hudesman D; Varma S; Fischer M; Sultan K; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Siegel CA; Dulai PS
    Inflamm Bowel Dis; 2019 Oct; 25(11):1854-1861. PubMed ID: 31050734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
    Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
    Feagan BG; Lasch K; Lissoos T; Cao C; Wojtowicz AM; Khalid JM; Colombel JF
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):130-138.e7. PubMed ID: 29857145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Essat M; Tappenden P; Ren S; Bessey A; Archer R; Wong R; Lobo A; Hoque S
    Pharmacoeconomics; 2016 Mar; 34(3):245-57. PubMed ID: 26477040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
    Narula N; Wong ECL; Marshall JK; Jairath V; Dulai PS; Reinisch W
    Am J Gastroenterol; 2023 Jan; 118(1):121-128. PubMed ID: 36066459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.
    Zagórowicz E; Cichoż-Lach H; Kopertowska-Majchrzak M; Eder P; Stawczyk-Eder K; Talar-Wojnarowska R; Zatorski H; Solarska-Półchłopek A; Filip R; Janiak M; Skrobot K; Kłopocka M; Liebert A; Kaczka A; Wojciechowski K; Drygała S; Michalak A
    Adv Clin Exp Med; 2024 Jan; 33(1):69-77. PubMed ID: 37166016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Feagan BG; Patel H; Colombel JF; Rubin DT; James A; Mody R; Lasch K
    Aliment Pharmacol Ther; 2017 Jan; 45(2):264-275. PubMed ID: 27859410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
    Mosli MH; MacDonald JK; Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; Khanna R; Feagan BG
    Inflamm Bowel Dis; 2015 May; 21(5):1151-9. PubMed ID: 25844963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
    Vermeire S; Hanzel J; Löwenberg M; Ferrante M; Bossuyt P; Hoentjen F; Franchimont D; Palatka K; Peeters H; Mookhoek A; de Hertogh G; Molnár T; van Moerkercke W; Lobatón T; Clasquin E; Hulshoff MS; Baert F; D'Haens G;
    J Crohns Colitis; 2024 Apr; 18(4):540-547. PubMed ID: 37934813
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study.
    White JR; Din S; Ingram RJM; Foley S; Alam MA; Robinson R; Francis R; Tucker E; Jalal M; Elphick D; Atallah E; Norman A; Amin M; Sajjad A; Heggs N; Meadowcroft S; Moran GW
    Scand J Gastroenterol; 2020 Aug; 55(8):907-916. PubMed ID: 32657179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
    Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.
    Tarabar D; El Jurdi K; Traboulsi C; Yvellez O; Milenkovic Z; Petrovic S; Subotic B; Gils A; Brocic T; Brcerevic I; Latinovic O; Jocic T; Rubin DT
    Inflamm Bowel Dis; 2022 Oct; 28(10):1549-1554. PubMed ID: 35078235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
    Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
    Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
    Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
    Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
    Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.